1. INTRODUCTION {#sec1}
===============

Medulloblastoma (MB) is the most common malignant pediatric brain tumor, accounting for nearly 20% of all childhood central nervous system (CNS) malignancies \[[@r1]\]. The major histopathological classification of these tumors consist of the classic, desmoplastic nodular (MB/N), MB with extensive nodularity (MBEN), and large cell/anaplastic (LC/A) types. Prognosis has varied between these subtypes, with MBEN having a better outcome than the LC/A tumors \[[@r2], [@r3]\]. Current treatment strategies are tailored based on clinico-radiological risk criterion. These include the standard-risk (SR) or high-risk (HR) group. Children who are older than 3 years with no evidence of metastatic disease (M0), post-surgical residual tumor less than 1.5 cm^2^, and histologically non-anaplastic are categorized as SR, while the remaining are considered HR \[[@r4]\]. Children younger than 3 years who have significant residual disease following surgery, LC/A histology and metastatic disease fare worse with poor survival outcome \[[@r5]\]. A multimodality therapeutic approach is used to treat children over three years, which includes maximal safe surgical resection, concurrent chemotherapy with craniospinal radiation (CSI) and a boost to the tumor bed, usually followed by adjuvant chemotherapy \[[@r6], [@r7]\]. Children younger than 3 years are treated postoperatively with high-dose chemotherapy as an irradiation-avoiding strategy or with non-high-dose chemotherapy during induction followed by a reduced dose of conformal radiotherapy (CRT) to the tumor bed \[[@r8]-[@r10]\], NCT00602667/SJYC07, NCT02724579.

Over the last two decades, many clinical trials have been pursued (Table **[1](#T1){ref-type="table"}**). Though this has resulted in increased overall survival (OS), long-term side effects are concerning \[[@r11]\]. These include neurocognitive deficits, hearing loss, endocrine dysfunction and increased incidence of secondary malignancies \[[@r12], [@r13]\]. The uniform treatment approach based on the histopathology and risk group has been undermined by the unpredictable relapse and heterogeneity in survival outcome, and nearly one-third of patients die within 5 years of diagnosis. Four subgroups of tumors (WNT, SHH, Group 3 and Group 4) with distinctive molecular profiles and prognosis, have now been identified. These findings have been validated in multiple studies, and it is now clear that critical prognostic factors are defined not only by histology, but also by subgroup assignments and metastatic status \[[@r14]\]. These molecular revelations now explain the variable survival outcomes when children are treated uniformly solely based on histopathological criterion and clinical risk.

2. TREATMENT STRATEGIES BASED ON RISK STRATIFICATION {#sec2}
====================================================

For SR MB patients, following surgery, a reduced-dose radiation strategy using CSI to a total dose of 23.4 Gy plus a boost to the posterior fossa up to a total dose of 54-55.8 Gy, has been usually used along with concurrent and adjuvant chemotherapy. A large study was performed on 379 evaluable patients with SR MB who were treated with 23.4 Gy of CSI and 55.8 Gy of posterior fossa RT and randomly assigned to one of the two adjuvant chemotherapy regimens: lomustine (CCNU), cisplatin, and vincristine; or cyclophosphamide, cisplatin, and vincristine. Five-year event free survival (EFS) and overall survival (OS) for the cohort of 379 patients were 81% +/- 2.1% and 86% +/- 9%, respectively \[[@r15]\]. A European study (HIT-SIOP PNET4) on 340 children aged 4 to 21 years with SR MB compared conventional CSI at a dose of 23.4 Gy plus boost with hyperfractionated CSI at a dose of 36 Gy plus boost, followed by similar chemotherapy regimens for both arms. A follow-up of 4.8 years did not find a significant difference in the survival rates between the two therapeutic strategies \[[@r16]\]. The Children's Oncology Group (COG) completed a study (ACNS0331) on 513 children with SR MB, evaluating and comparing limited target volume boost irradiation (tumor bed versus posterior fossa) and reduced-dose CSI (18 Gy versus standard 23.4 Gy) in a subset of patients between 3-7 years of age, with an intent to alleviate toxicity without compromising OS and EFS. The results of this study are pending, but preliminary data show no evidence of a significant difference in EFS between the two fields of radiation, and CSI cannot be safely reduced from 23.4 Gy to 18 Gy without compromising clinical outcome (NCT00085735). Currently, an ongoing study (SIOP PNET5) is evaluating the role of β-catenin status in SR MB. Patients with β-catenin-positive tumors are assigned to a low-risk (LR) treatment arm (PNET 5 MB -- LR) and patients with other SR MB are assigned to a standard-risk treatment arm (PNET 5 MB -- SR). The LR patients receive reduced CSI to 18 Gy without carboplatin and reduced-intensity maintenance chemotherapy (NCT02066150).

For HR MB patients, an earlier study showed that the addition of adjuvant chemotherapy was effective in improving the rate of disease-free survival in children with poor-risk MB/PNET compared to those who received radiotherapy alone \[[@r17]\]. Studies by the French Society of Pediatric Oncology (SFOP), COG 921, and HIT91 for HR MB did not fare well with an EFS of less than 50% \[[@r18]-[@r20]\]. Though these studies used multiple chemotherapy regimens, inferior survival outcome was seen, likely due to the delay in starting radiation therapy. Another study randomized 112 HR MB patients to receive chemotherapy before or after radiation followed by similar adjuvant chemotherapy. An improved 5 year EFS of 66 and 70% for the respective arms was noted, though no statistical difference in OS was achieved for patients receiving post-surgical chemotherapy before or after radiation \[[@r21]\]. A more recent study treated HR patients with 36 Gy CSI along with weekly vincristine and carboplatin, followed by chemotherapy with cyclophosphamide and vincristine (Reg A), and later cisplatin was added (Reg B) to the adjuvant therapy regimen. The 5-year OS was 82% and 68% for the respective arms, which showed improved survival rates over historical controls for these patients \[[@r22]\]. A study was performed on 123 metastatic MB patients to evaluate prognostic relevance of clinical and biologic parameters. Treatment included induction chemotherapy, dose-escalated hyperfractionated CSI, followed by maintenance chemotherapy. The 5 year OS was 74% for the entire group with a 100% OS seen in those tumors driven by WNT pathway \[[@r23]\].

3. TARGETED THERAPIES {#sec3}
=====================

Recent clinical trials have focused on using newer drugs, targeting signaling pathways and molecules which have emerged as key oncogenic drivers of these tumors. The Notch signaling pathway, which induces proliferation and survival of neural precursors, has been shown to drive MB formation \[[@r24]\]. Preclinical studies demonstrated overexpression and the role of vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGFR), histone deacetylase (HDAC), and the cyclooxygenase 2 (COX2) proteins in inducing MB formation \[[@r25]\]. These events have led to clinical trials targeting these tumorigenic drivers. A completed clinical trial targeting the Notch pathway by inhibiting the γ-secretase, using a weekly dose of MK-0752 (γ-secretase inhibitor) in 10 patients with recurrent CNS malignancies (including MB), showed safety and inhibition of NOTCH expression. No objective responses were noted in any patients. Future trials using MK-0752 in combination with targeted agents (*e.g*., mTOR/Akt inhibitors) or chemotherapeutic agents (*e.g*., temozolomide) are planned to be explored in phase I trials \[[@r26]\]. The role of bevacizumab (VEGF inhibitor) has been explored alone and in combination with irinotecan (topoisomerase I inhibitor) and/or temozolomide (DNA alkylating agent) with good tolerability and variable response \[[@r27], [@r28]\].

4. HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL RESCUE {#sec4}
==========================================================

As an irradiation-avoiding strategy, the role of high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCR) has been explored for newly diagnosed and relapsed MB, with some studies showing good clinical outcome and an effective alternative therapy in younger children. Though HDC with ASCR has been shown to improve survival rates in a subset of patients, the incidence of morbidity and mortality due to veno-occlusive disease and infections have at times undermined the modest survival outcome \[[@r29]-[@r32]\].

5. THE MOLECULAR ERA OF MEDULLOBLASTOMA {#sec5}
=======================================

Over the last decade, various transcriptional profiling studies have identified four molecular subgroups of MB: WNT, SHH, Group 3, and Group 4 \[[@r33]-[@r39]\]. This has ushered a new era in the realm of MB genomics, and these subgroups are now clearly identified with distinguishing features based on demographics, histology, chromosomal profile, driver genes, and outcome (Table **[2](#T2){ref-type="table"}**) \[[@r40]-[@r44]\]. Cancer genomic sequencing studies have provided insight into the drivers of these subgroups, through recurrent structural alterations, somatic mutations, and epigenetic deregulation \[[@r45]-[@r53]\]. Parallel research endeavors have also provided a superior understanding of important signaling pathways and mechanisms that induce therapeutic resistance. This has now enabled risk stratification of MB based on the molecular subtypes of these tumors and provide insights to newer therapies (Fig. **[1](#F1){ref-type="fig"}**).

5.1. WNT Subgroup Medulloblastoma {#sec5.1}
---------------------------------

WNT MBs are the least common subgroup, accounting for about 10% of all MBs \[[@r54]-[@r56]\]. They occur equally between males and females, with a median age of \~10 years at diagnosis \[[@r47]\]. The tumors rarely metastasize and are usually located in the midline of the brain, infiltrating the brainstem \[[@r57]\]. Most of these tumors have classic histology and the prognosis for this subgroup of patient population is excellent in comparison to the other subgroups, with a five-year survival rate of \~95% \[[@r44]\]. All patients in the WNT subgroup younger than 16 years at the age of diagnosis are considered to have low-risk disease (\>90% survival) based on the current risk stratification consensus. This study also concluded the prognosis of children older than 16 years at diagnosis remains ill-defined \[[@r58]\]. Molecular-based clinical trials are currently underway to evaluate the potential of radiation therapy and chemotherapy de-escalation to reduce treatment-associated side effects, while maintaining equivalent survival rates (SJMB12, NCT01878617, PNET 5, NCT02066150, ACNS1422, and NCT02724579).

Historically, Turcot syndrome described the concurrence of a primary brain tumor, typically a MB or glioma, and multiple colorectal adenomas \[[@r59]\]. As the genetics of familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC) were elucidated, it became clear that the majority of brain tumors associated with FAP were MBs, while gliomas were more common with HNPCC. FAP is caused by inactivating, germline mutations in the *APC* tumor suppressor gene. Loss of function of the APC protein leads to nuclear accumulation of the WNT pathway effector molecule β-catenin. β-catenin then complexes with the T cell factor/lymphoid enhancer-binding factor (TCF/LEF) family of transcription factors and recruits other transcriptional co-activators to activate the target genes in canonical WNT/β-catenin signaling pathway---a pathway that plays a crucial role in many diverse processes governing embryonic development and disease, including cancer progression \[[@r60]-[@r62]\]. This led to the discovery of somatic activating point mutations in *CTNNB1*, the gene that encodes β-catenin \[[@r63]\]. More than 90% of the tumors in this subgroup have *CTNNB1* mutations that cause production of a mutant β-catenin protein, that is resistant to degradation and accumulates in the nucleus to hyper-activate WNT pathway genes \[[@r46]-[@r49]\].

In addition to the nearly ubiquitous *CTNNB1* mutations, other prevalent recurrent mutations in this subgroup include *DDX3X* (50%), *SMARCA4* (26%), *KMT2D* (13%), and *TP53* (13%) \[[@r44], [@r46]-[@r49]\]. Mutations in *DDX3X*, which encodes a DEAD-box RNA helicase, have been shown to promote cell viability and proliferation by potentiating the transactivation capacity of mutant β-catenin and also have been shown to maintain the lineage of lower rhombic lip progenitor cells, the proposed cells of origin for WNT MBs \[[@r48], [@r49], [@r57]\]. *SMARCA4* and *KMT2D* (also known as *MLL2*) encode proteins involved in chromatin remodeling. Specifically, *SMARCA4* has been identified as one of the transcriptional co-activators associated with the β-catenin-TCF/LEF transcription factor complex \[[@r64]\]. Mutations have also been identified in other transcriptional co-activators associated with the β-catenin-TCF/LEF complex as well (*e.g*., *CREBBP*, *TRRAP*, *MED13*) \[[@r49], [@r65], [@r66]\]. Though p53 mutations are frequently associated with the WNT subgroup of MB, they are not prognostic and not associated with the Li-Fraumeni syndrome, unlike in the SHH subgroup where they are related to a very bad prognosis \[[@r67]\]. The mutational landscape of WNT MB suggests that different subsets of tumors may be modified and potentially dependent on specific chromatin remodeling and RNA helicase complexes, affording potential opportunities for targeted therapy.

5.2. SHH Subgroup Medulloblastoma {#sec5.2}
---------------------------------

Sonic hedgehog (SHH) pathway-driven MBs comprise approximately 30% of cases \[[@r47]\]. There is a bimodal age distribution in patients with this subgroup of tumors, with increased incidence among infants and young children less than 5 years of age and a second increase in frequency among older adolescents and adults greater than 16 years of age. These tumors are found in the cerebellar hemispheres, a location unique to this subtype \[[@r57], [@r68]\]. Metastatic disease at diagnosis occurs in less than 25% of cases. All MB histologies are represented among SHH MBs, with desmoplastic nodular and MBEN variants almost exclusively found in this subgroup \[[@r55], [@r69]\].

The prognosis for these patients is intermediate, with a five-year survival rate of \~75% \[[@r44]\]. Based on the current risk stratification consensus, patients with SHH MBs fall into the standard-risk stratum (75-90% survival)---unless they have: 1) metastatic disease and/or *MYCN*-amplified tumors, which constitutes high-risk disease (50-75% survival), or 2) tumors with *TP53* mutations, which is considered very high risk (\<50% survival) \[[@r58]\]. The tumors with *TP53* mutations are highly enriched in children aged 3-17 and are frequently associated with LC/A morphology, constituting a higher risk group with significantly worse outcomes. In one cohort of MB, TP53 mutations accounted for 72% of deaths in children older than 5 years with SHH tumors \[[@r70]\].

The association of MBs with activation of the SHH signaling pathway was first identified in patients with Gorlin syndrome (nevoid basal cell carcinoma syndrome), who have a high prevalence of basal cell carcinoma and are predisposed to desmoplastic and MBEN MBs that commonly present in infancy, among other various neoplasms \[[@r71]-[@r73]\]. Gorlin syndrome is primarily caused by germline mutations in the *PTCH1* tumor suppressor gene, which encodes patched 1 (PTC1), a cell-surface receptor for SHH and other hedgehog homologues \[[@r74],[@r75]\]. In the absence of ligand binding, PTC1 inhibits the G protein-coupled receptor smoothened (SMO), thus acting as a negative regulator of the SHH signaling pathway \[[@r76]\]. The binding of SHH to PTC1 activates SMO, which leads to the release of GLI transcription factors from the cytoplasmic sequestration of SUFU, another negative regulator in the pathway. This results in the nuclear localization of GLI transcription factors and activation of target genes, including those involved in cellular proliferation, such as *MYCN* and *CCND1* \[[@r77]\]. Thus, while germline or somatic mutations in *PTCH1* are a hallmark feature in this subgroup, occurring in almost 30% of tumors, recurrent mutations and DNA structural alterations in the other SHH pathway genes acting downstream of *PTCH1* (*e.g*., *SMO*, *SUFU*, *GLI2*) have also been identified \[[@r35], [@r46]-[@r49], [@r78]\].

Targeted therapies for SHH-driven MBs that inhibit SMO (*e.g*., vismodegib, GDC-0449; and sonidegib, NVP-LDE225) have entered clinical trials \[[@r79]-[@r81]\]. A recently completed phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma, showed that this drug was well tolerated with responses \[[@r82]\]. However a notable side-effect was premature closure of the growth plate, as also demonstrated in preclinical models \[[@r83]\]. While clinical response has been achieved in some patients with SHH MB, resistance to SMO inhibitors quickly emerges in these patients, prompting investigations into the mechanisms of acquired resistance and strategies to overcome these adaptations \[[@r84]-[@r88]\]. One strategy involves targeting the PI3K/Akt pathway, which is mutated in some tumors with acquired SMO inhibitor resistance, in combination with SMO antagonists \[[@r86]\]. Another promising combination therapy involving arsenic trioxide, which acts at the level of the GLI transcription factors, and itraconzaole, which inhibits SMO through a distinct mechanism, has been shown in pre-clinical experiments to be effective in SHH MBs that become resistant to SMO inhibitors \[[@r89]\]. Meanwhile, patients who did not respond to SMO inhibition in the first place tend to have mutations or amplifications in downstream SHH pathway genes (*e.g*., *SUFU*, *MYCN*, *GLI2*), causing inherent resistance to the SMO inhibitor \[[@r50], [@r78], [@r85]\]. These findings support that multiple levels of genomic evidence (*i.e*., sequencing, copy number alterations) will be imperative for the identification of potential responders and non-responders to target-based MB therapy and also for pinpointing likely candidates that mediate therapeutic resistance.

5.3. GROUP 3 Subgroup Medulloblastoma {#sec5.3}
-------------------------------------

Group 3 constitutes about 25% of MBs \[[@r47]\]. This subgroup carries the worst prognosis, with a five-year survival rate of \~50% \[[@r44]\]. While Group 3 MBs are considered to be standard risk (75-90% survival) if they do not have MYC amplification and are not metastatic, if they are metastatic at the time of diagnosis, they are classified as very high risk (\<50% survival). Risk group for those tumors who are *MYC* amplified and non-metastatic is unknown \[[@r58], [@r59]\]. These tumors affect predominantly infants and young children (rarely teenagers) and occur twice as often in males as in females. Tumors are located in the midline/fourth ventricle \[[@r68]\]. Approximately 40-45% of patients already have metastatic disease at the time of diagnosis \[[@r69]\]. Histologically, Group 3 MBs are either classic or LC/A, with the highest prevalence of LC/A histology among the subgroups (40%).

The genetic basis for Group 3 MB is poorly understood \[[@r41]-[@r44]\]. No germline mutations that predispose patients to Group 3 MBs have been described. Amplification of the *MYC* proto-oncogene is nearly exclusive to this subgroup, but occurs in just 17% of these tumors \[[@r35], [@r38], [@r46]-[@r49], [@r69]\]. A few other recurrent somatic genomic aberrations have been reported, primarily in genes encoding chromatin remodeling proteins (*e.g*., *SMARCA4* in 11%, *KMT2D* in 4%) and demethylases. However, over 50% of Group 3 tumors do not carry any of these genomic aberrations and, instead, have widespread chromosomal alterations, indicating a high level of genomic instability \[[@r42], [@r44]\].

Recently, one study shed some light on the role that these chromosomal alterations may play in the pathogenesis of Group 3 and Group 4 MB. Northcott and colleagues identified a series of atypical duplications, deletions, inversions, and complex rearrangements that converge to specifically activate the growth factor independent 1 family proto-oncogenes *GFI1* and *GFI1B* through enhancer hijacking. While copy number alterations are not seen in the genes themselves, these intra- and inter-chromosomal structural variations repositioned *GFI1* and *GFI1B* from transcriptionally silent regions of the genome to regions adjacent to active enhancers, including super-enhancers, thereby activating oncogene expression. Activation of *GFI1* and *GFI1B* in a mutually exclusive manner was found in 30-40% of Group 3 MBs, such that they are now the most prevalent known oncogenic drivers in this subgroup. Currently unknown is whether *GFI1* and *GFI1B* represent suitable druggable candidates for targeted therapy, or perhaps reveal synthetic lethal pathways that may be modulated to improve clinical outcome \[[@r52]\].

5.4. GROUP 4 Subgroup Medulloblastoma {#sec5.4}
-------------------------------------

Group 4 MBs are the most prevalent subgroup, accounting for nearly 35% of cases \[[@r47]\]. The prognosis for these patients is intermediate, with a five-year survival rate of \~75% \[[@r44]\]. Group 4 tumors are actually considered low-risk (\>90% survival) if they are non-metastatic and have loss of chromosome 11 \[[@r58]\]. If tumors are non-metastatic, but do not have loss of chromosome 11, they are considered standard-risk (75-90% survival). However, if metastatic disease is present at diagnosis, they are considered high-risk (50-75% survival). These tumors affect all ages and are the most skewed in gender distribution, affecting males three times as commonly as females. Like Group 3, Group 4 tumors are located in the midline/fourth ventricle, and nearly 35-40% of patients already have metastases at diagnosis \[[@r68], [@r69]\]. Also similar to Group 3, Group 4 MBs have either classic or LC/A histology, although LC/A histology is much more infrequent.

The biology of Group 4 MBs is the least understood among the four subgroups \[[@r41]-[@r44]\]. Cytogenetically, the characteristic feature of this subgroup is isochromosome 17q, which is found in over 80%, and for which a driver oncogene and/or tumor suppressor gene remains unknown \[[@r35], [@r38], [@r68]\]. Group 4 tumors appear to share some biological similarities with Group 3 tumors as there is significant overlap of recurrent genetic mutations and copy number alterations between the two subtypes \[[@r35], [@r38], [@r46]-[@r49]\]. However, while *MYC* is amplified in Group 3, the proto-oncogenes *MYCN* and *CDK6* are recurrently amplified in Group 4 MBs, but only in 6% and 5% of tumors, respectively. The most frequent mutation in this subgroup, occurring in 13%, is in *KDM6A*, a lysine demethylase regulating H3K27 methylation, a repressive chromatin mark important in cancer and stem cell biology \[[@r42], [@r44]\]. The most frequent focal somatic copy number gain is a tandem duplication of *SNCAIP*, a gene associated with Parkinson's disease, found in 10% of tumors. The biology of *KDM6A* and *SNCAIP* in Group 4 MB pathogenesis remains poorly understood and is a current area of active investigation.

Though molecular subgrouping has revolutionized medulloblastoma classification, identification of significant heterogeneity within these subgroups are now emerging. 12 different subtypes of MB are now identified including two in infants with SHH MB with disparate outcomes and biology. Integrative analysis using similarity network fusion (SNF) has now further delineated group 3 from group 4 medulloblastoma. These recent revelations of MB subtypes within the four molecular subgroups determined through integrative clustering have important implications for stratification and profiling future clinical trials \[[@r90]\].

6. ROLE OF EPIGENETIC MODIFIERS {#sec6}
===============================

One theme that has emerged from the extensive sequencing studies recently published is the important role epigenetic deregulation plays in the pathogenesis of MB \[[@r91]\]. Histone modifiers are recurrently mutated and amplified in these genomes \[[@r44], [@r46]-[@r49], [@r92]-[@r94]\]. About a third of MBs across all subgroups carry mutations in histone methyltransferases (HMTs), histone demethylases (HDMs), histone acetyltransferases (HATs), histone deacetylases (HDACs), or other chromatin-associated genes (Table **[3](#T3){ref-type="table"}**) \[[@r44]\].

Histone methylation, in particular, is deregulated in Group 3 and Group 4 tumors \[[@r49]\]. H3K27 trimethylation (H3K27me3) is a histone mark that maintains the undifferentiated state of stem cells by repressing lineage-specific genes \[[@r95]\]. H3K27me3 is written by histone methyltransferases (*e.g*., EZH2) and erased during differentiation by demethylases (*e.g*., KDM6A) \[[@r96]-[@r98]\]. With the removal of repressive H3K27me3 marks and coordinated deposition of H3K4me3 activating marks, chromatin remodelers (*e.g*., CHD7) are recruited to H3K4me3 sites to promote differentiation \[[@r99]-[@r101]\]. Phase I studies in children with relapsed/refractory CNS tumors showed vorinostat (HDAC inhibitor) was well-tolerated when combined with either temozolomide (NCT01076530) or bortezomib, a proteasome inhibitor (NCT00994500), highlighting the potential role epigenetic modifiers.

As discussed above, *KDM6A* is a lysine demethylase regulating H3K27 methylation and is the most commonly mutated gene in Group 4 MBs (13%). These tumors also harbor recurrent mutations in *CHD7* and *ZMYM3*, which converge on the regulation of gene expression by H3K4me3 \[[@r93]\]. Furthermore, both Group 3 and Group 4 MBs overexpress *EZH2* as a result of chromosome 7 gain---but not in those tumors carrying inactivating mutations in *KDM6A*, *CHD7*, or *ZMYM3* mutations \[[@r49]\]. Thus, Robinson and colleagues proposed that Group 3 and Group 4 MBs preserve stem-like signatures through a variety of mechanisms: accumulation of repressive H3K27me3 marks (EZH2 overexpression), maintenance of H3K27me3 (*KDM6A* inactivation), or abrogation of H3K4me4-mediated differentiation (*CHD7* and *ZMYM3* inactivation) \[[@r49], [@r93]\].

Accordingly, there has been growing interest in investigating therapeutics that target epigenetic regulators. One novel mechanism of targeting histone modifications is by inhibiting the readers of acetylation, the BET bromodomain proteins (*e.g*., BRD4) \[[@r102]\]. Bromodomains recognize and bind to acetylation motifs on open chromatin (*e.g*., H3K27ac) at active enhancer and super-enhancer sites, often localizing to promoters of key transcription factors, such as *MYC* \[[@r103]-[@r105]\]. Inhibitors of bromodomains, such as JQ1, have been shown to be effective in *MYC*-driven, Group 3 MBs \[[@r106]-[@r108]\] as well as in SHH MBs with resistance to SMO inhibitors (both acquired and inherent) \[[@r109]\]. Inhibitors of EZH2 are also promising in targeting the subset of Group 3 and Group 4 MBs that overexpress EZH2 \[[@r110]\]. Additionally, Pei and colleagues recently performed a high-throughput screen that identified HDAC inhibitors as potent inhibitors of MYC-driven MB in preclinical models \[[@r111]\]. Furthermore, they showed that the combination of HDAC inhibitors with PI3K antagonists (specifically, panobinostat and buparlisib) act synergistically against tumor growth. Given the potentially rapid adaptation of MB cells to targeted ablation, upfront identification of effective combination therapies and potential resistance mechanisms is needed to improve therapeutic efficacy.

7. RECURRENT DISEASE AND THERAPEUTIC RESISTANCE {#sec7}
===============================================

Recurrent MB is almost uniformly fatal, with a 2-year survival rate of 9% \[[@r19]\]. The mechanism(s) and genetic basis by which MB cells escape therapy and drive disease relapse is still poorly understood. Several studies were published recently that serve to enhance this understanding.

Phoenix and colleagues focused on the role of the microenvironment in determining treatment sensitivity, specifically what allows for the excellent prognosis of WNT-subtype tumors, such that they can be curable even when metastatic, compared to other subgroups \[[@r112]\]. They found that while other MB subgroups have normal central nervous system vasculature, WNT MBs lack a functional blood-brain barrier (BBB), which facilitates increased access of systemic chemotherapy to WNT tumors and contributes to the excellent treatment response. This disruption in the BBB is driven by the paracrine signaling of WNT antagonists secreted by the tumor, presumably produced in a negative feedback response to the constitutive mutant β-catenin activity that drives the tumor. These WNT antagonists block the normal process of paracrine WNT signaling in neighboring endothelial cells that induces angiogenesis and barriergenesis and maintains the BBB throughout life \[[@r113], [@r114]\]. Thus, the failure of chemotherapy to adequately reach its target is one mechanism by which tumor cells could escape treatment, and inhibiting WNT to disrupt the BBB and improve chemotherapy penetration in other MB subgroups is a future area of study.

Another mechanism by which disease could recur is through therapeutic resistance in a progenitor, stem cell-like population that can subsequently reconstitute the tumor. Vanner and colleagues identified such a population of Sox+ cells in a mouse model of SHH MB \[[@r115]\]. They showed that these cells are resistant to both anti-mitotic therapy and the targeted SMO inhibitor vismodegib, such that they become enriched after therapy. These cells also express a quiescent stem cell signature and can reconstitute the tumor hierarchy at MB relapse. Eradicating this progenitor cell population with novel therapies in addition to tumor debulking with current therapies may be an efficacious combination in order to prevent disease relapse. There is also the need to identify novel therapies targeting the very high risk group of SHH tumors with *TP53* mutations as multivariable analysis has revealed that TP53 status is the most important risk factor for SHH medulloblastoma. This subset of tumors is the leading cause for therapeutic resistance and poor outcomes in the SHH subgroup \[[@r70]\].

Historically, when MB recurs, patients have been treated based on the premise that the recurrent tumor is biologically similar to the tumor at the time of diagnosis. This, however, has been an unsubstantiated assumption that Morrissy and Garzia *et al*. recently showed is untrue in the vast majority of cases \[[@r116]\]. The authors performed whole-genome sequencing on 33 pairs of diagnostic and post-recurrent MBs and found that the dominant clone after therapy shares only \<12% of genetic events found in the dominant clone at diagnosis. Instead, it appears that the dominant clone at recurrence may arise through clonal selection of a minor clone present at the time of diagnosis. Nevertheless, despite this genetic divergence, the tumor subgroup (WNT, SHH, Group 3, or Group 4) remains stable across recurrence and metastasis \[[@r117], [@r118]\] suggesting that certain molecular aspects of MBs are maintained during tumor evolution. Thus, prior clinical trials for novel therapies designed to target tumors based on their genetic profile at the time of diagnosis may have been doomed to fail as these targets may have no longer been present at recurrence. It will be essential that future target-based clinical trials for MB ensure that the specific driver lesions are maintained at relapse if trials are to be designed in patients with recurrent MB.

CONCLUSION
==========

The identification of the molecular subtypes of MB and ongoing research advances have incited a new era in personalized therapeutic approaches for these tumors. Future clinical trials and efforts are now looking into deescalating therapy in the WNT subgroup, which carries an excellent prognosis. Identifying methodologies to overcome drug resistance in the SHH variant is important, as downstream molecules of this pathway are emerging as key players inducing therapeutic failures and may serve as potential druggable targets. The major challenge and the focus lie in improved understanding of the elusive molecular biology of Group 3 and 4 tumors as well as judicious intensification of the therapy in these subtypes to improve clinical outcome. With the continuing surge of genomic/epigenomic data of these subgroups, the formidable task lies ahead in the comprehensive evaluation of this knowledge, and being able to deliver the most promising clinical trials, more so for the patients with high-risk and recurrent MB.
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###### 

Clinical trials.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **S. No.**   **Clinical**\                  **Patients**\               **Treatment**\                                                                   **Survival Rate**                                                                      **Refs.**
               **Trial**                      **(Number/Age in (Year)**   **Risk Group**                                                                                                                                                          
  ------------ ------------------------------ --------------------------- -------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ------------
  1\.          Gajjar *et al*, 2006\          134\                        VCR, CPM, CDDP,\                                                                 5 year OS: 83% SR group\                                                               \[[@r4]\]
               SJMB 96                        3-21 yrs                    XRT 23.4 Gy (SR) or 36.0-39.6 Gy (HR)                                            70% HR group                                                                           

  2\.          Von Bueren *et al*, 2011\      45\                         No XRT\                                                                          5 year OS: 80% +/- 6%                                                                  \[[@r5]\]
               HIT 2000                       \< 4 yrs                    CPM, Mtx, Carboplatin, VP16, VCR, intraventricular Mtx\                                                                                                                 
                                                                          M0                                                                                                                                                                      

  3\.          Rutkowski *et al*, 2008\       29\                         No XRT\                                                                          10-year OS: 58.8% ± 11.9% (complete resection), 66.7% ± 15.7% (incomplete resection)   \[[@r8]\]
               HIT-SKK'87                     \< 3 yrs                    Procarbazine, Ifosfamide, VP16, CDDP, Ara-C, Mtx\                                                                                                                       
                                                                          26 pts M0/M1, 3 pts M2/M3                                                                                                                                               

  4\.          Chi *et al*, 2004\             21\                         VCR, CDDP, VP16, CPM, Mtx\                                                       3-year OS: 60%                                                                         \[[@r9]\]
               Head Start II                  \<10 yrs                    HR                                                                                                                                                                      

  5\.          Packer *et al*\                379\                        XRT with VCR\                                                                    5 year OS: 86% ± 9%                                                                    \[[@r15]\]
               2006\                          3-21 yrs                    Reg A: CCNU, VCR CDDP,\                                                                                                                                                 
               Phase III                                                  Reg B: CDDP, CPM, VCR\                                                                                                                                                  
                                                                          SR                                                                                                                                                                      

  6\.          Kortmann *et al*, 2000\        137\                        XRT\                                                                             3 year relapse-free survival:\                                                         \[[@r20]\]
               HIT'91                         3-18 yrs                    Neoadjuvant arm: Ifosfamide, VP16, Mtx, CDDP, Ara-C\                             0.70+/-0.08                                                                            
                                                                          Adjuvant arm: VCR, CDDP, CCNU\                                                                                                                                          
                                                                          SR and HR                                                                                                                                                               

  7\.          Tarbell *et al* 2013\          154\                        Randomized to pre XRT CT (CT1) or post XRT CT (RT1)\                             5 year OS:\                                                                            \[[@r21]\]
               POG 9031                       3-21 yrs                    CDDP, VP16,\                                                                     73.1% CT1 arm, 76.1% RT1 arm                                                           
                                                                          Consolidation with CPM, VCR\                                                                                                                                            
                                                                          HR                                                                                                                                                                      

  9\.          Jakacki *et al*, 2011\         161\                        Carboplatin and VCR during XRT\                                                  5-year OS:\                                                                            \[[@r22]\]
               COG Phase I/II                 3-21 yrs                    Maintenance regimen A: CPM and VCR\                                              Regimen A - 82% +/- 9%\                                                                
                                                                          Maintenance regimen B: CDDP, CPM, VCR\                                           Regimen B 68% +/- 10%                                                                  
                                                                          HR                                                                                                                                                                      

  10\.         Von Bueren *et al* 2016        123\                        Induction CT, dose escalated CSI XRT, maintenance CT\                            5 year: EFS 62%, OS 74% for all patients\                                              \[[@r23]\]
                                              4-21 yrs                    HR                                                                               5 year OS 100% for WNT and 20% for *MYCC/MYCN* amplification tumors                    

  11\.         Perez-Martinez *et al*, 2005   19\                         XRT for patients \> 4 years\                                                     2 year EFS:\                                                                           \[[@r29]\]
                                              2-15 yrs                    Induction CT and then HDCT (busulfan-melphalan, busulfan-thiotepa, topotecan)\   37.67+/-14% in all patients 57+/-15% for the HR group.                                 
                                                                          HR/Recurrent tumors                                                                                                                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** Ara-C, cytosine arabinoside; CCNU, Lomustine; CDDP, cisplatin; CPM, cyclophosphamide; CSI, craniospinal radiation; CT, chemotherapy; EFS, event-free survival; HDCT, high dose chemotherapy; HR: high risk; Mtx- methotrexate; M0: no metastasis; OS, overall survival, SR, standard risk; XRT, radiotherapy.

###### 

Characteristics of medulloblastoma subgroups.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            **WNT (10%)**                                            **SHH (30%)**                                                                                                    **Group 3 (25%)**                                                                                                  **Group 4 (35%)**
  ------------------------- -------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------
  **Clinical Features**                                                                                                                                                                                                                                                                                                  

  Age                       Older children and adults (median age \~10 years)        Bimodal: \< 5 years & \>16 years; less common in children aged 5-16 years                                        Infants and young children                                                                                         Children (median age \~ 9 years); can occur in all age groups

  Gender Ratio (M:F)        \~1:1                                                    \~1.5:1                                                                                                          \~2:1                                                                                                              \~3:1

  Histology                 Classic; rarely LC/A                                     Classic \> desmoplastic nodular \> LC/A \> MBEN                                                                  Classic \> LC/A                                                                                                    Classic; rarely LC/A

  Proposed Cell of Origin   Lower rhombic lip progenitor cells                       CGNPs of the EGL and cochlear nucleus; neural stem cells of the subventricular zone                              Prominin 1^+^/lineage^-^ neural stem cells; CGNPs of the EGL                                                       Deep cerebellar nuclei in the nuclear transitory zone; upper rhombic lip progenitor cells

  Location of Tumor         Fourth ventricle; infiltrating brainstem                 Cerebellar hemispheres; rarely midline                                                                           Fourth ventricle; midline                                                                                          Fourth ventricle;\
                                                                                                                                                                                                                                                                                                                         midline

  Metastasis at Diagnosis   \~5-10%                                                  \~15-20%                                                                                                         \~40-45%                                                                                                           \~35-40%

  Prognosis\                \~95%                                                    \~75%                                                                                                            \~50%                                                                                                              \~75%
  (5-year survival)                                                                                                                                                                                                                                                                                                      

  **Genomic Features**                                                                                                                                                                                                                                                                                                   

  Cytogenetics              Monosomy 6                                               Loss of 9q, 10q, and 17p;\                                                                                       Loss of 10q, 16q, and 17p; Gain of 1q,\                                                                            Loss of 8, 10, 11, and 17p; Gain of 4, 7, 17q, and 18
                                                                                     Gain of 3q and 9p                                                                                                7, 17q, and 18                                                                                                     

  Driver Genes\             *CTNNB1*; *DDX3X*; *SMARCA4*; *KMT2D* (*MLL2*); *TP53*   *PTCH1*; *TP53*; *KMT2D* (*MLL2*); *DDX3X*; *MYCN* amplification; *BCOR*; *LDB1*; *TCF4*; *GLI2* amplification   *MYC* amplification; *PVT1* amplification; *SMARCA4*; *OTX2* amplification; *CTDNEP1*; *LRP1B*; *KMT2D* (*MLL2*)   *KDM6A*; *SNCAIP* gain*; MYCN* amplification; *KMT2C* (*MLL3*); *CDK6* amplification; *ZMYM3*
  (Most prevalent)                                                                                                                                                                                                                                                                                                       

  Expression\               WNT signaling                                            SHH signaling                                                                                                    MYC signature; photoreceptor GABAergic signature                                                                   Neuronal signature; glutamatergic signature
  Signature                                                                                                                                                                                                                                                                                                              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** LC/A, large cell/anaplastic; MBEN, medulloblastoma with extensive nodularity; CGNPs, cerebellar granule neuron precursors; EGL, external granule cell layer.

###### 

Most prevalent, recurrently mutated chromatin modifiers in medulloblastoma.

  **Function**                   **Gene**            **Somatic \|Mutation (%)**   **Subgroup Enrichment**               
  ------------------------------ ------------------- ---------------------------- ------------------------- --- --- --- ---
  H3K4 methyltransferase         *KMT2D (MLL2)*      5.8                          X                         X           
  *KMT2C* (*MLL3*)               2.6                                                                        X   X       
  Chromatin remodeler            *SMARCA4*           5.8                          X                             X       
  *CHD7*                         1.9                                                                        X   X       
  *ARID1B*                       1.2                 X                            X                                     
  Histone demethylase            H3K27me2 H3K27me3   *KDM6A*                      5.2                                   X
  H3K9me3 H3K36me3               *KDM4C*             1.0                                                        X   X   
  Transcriptional repressor      *BCOR*              2.0                                                    X           
  Transcriptional regulator      *LDB1*              1.6                                                    X           
  Histone acetyltransferase      *CREBBP*            1.3                          X                         X           
  *EP300*                        1.0                                              X                                     
  Associated with HAT complex    *TRRAP*             1.0                                                                
  Associated with HDAC complex   *ZMYM3*             1.3                                                            X   
  Histone phosphatase            *EYA4*              1.2                                                                

**Abbreviations:** HAT, histone acetyltransferase; HDAC, histone deacetylase.
